A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

Inclusion Criteria:

- Adults >/= 18 years old

- Histologically or cytologically confirmed advanced solid tumors that are refractory
to standard therapy or for which no standard therapy exists (Monotherapy and in
Cohorts A and B)

- At least one lesion measurable by RECIST not previously irradiated (Monotherapy and
in Cohorts A and B)

- Histologically confirmed DLBCL(Cohort C)

- Adequate organ and marrow function

- ECOG performance status of 0 or 1

- Willingness to provide consent for biopsy samples

Exclusion Criteria:

- Prior exposure to immunotherapy (either as a single agent or in combination)
including but not limited to CD137 or OX40 agonists, anti-CTLA-4, anti-PD-1, or
anti-PD-L1, anti-PD-L2 antibody or pathway-targeting agents

- History of organ transplant that requires use of immunosuppressives

- History of primary immunodeficiency or tuberculosis

- Active or prior documented autoimmune disease within the past 3 years

- Active or chronic viral hepatitis or history of any type of hepatitis within the last
6 months

- Major surgical procedure within 30 days prior to the first dose of investigational
product or still recovering from prior surgery

- Women who are pregnant or lactating